Our results support the involvement of SERCA in the etiopathology of LGMDR1 and lay the foundation to explore SERCA2 as well as UPS as novel molecular targets for the treatment of LGMDR1 muscular dystrophy. The gene discussed is CAPN3; the disease is muscular dystrophy.